文献速递头颈部肿瘤放疗

新辅助化疗能否改善T3-4N1期鼻咽癌生存?倾向性匹配分析

Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
PubMed 文献 · Radiat Oncol · 2020-07-02

该回顾性研究纳入282例T3-4N1期鼻咽癌患者,比较新辅助化疗联合同步放化疗与单纯同步放化疗的疗效。倾向性匹配后85对患者分析显示,两组5年OS、LRFS、DRFS、RFS均无显著差异,但新辅助化疗组急性血液学3-4级不良事件增加。治疗前淋巴结阳性状态(PLNC)是独立预后因素,阳性者生存更差。

要点

  • T3-4N1期鼻咽癌加用新辅助化疗未改善5年生存 outcomes。
  • 新辅助化疗组急性血液学3-4级不良事件发生率更高。
  • 治疗前淋巴结阳性状态(PLNC)阳性者5年OS、DRFS、RFS更低。

核心结论

  • 在T3-4N1期鼻咽癌中,额外的新辅助化疗与生存 outcomes 改善无关,但增加血液学3-4级不良事件。
  • 治疗前淋巴结阳性状态(PLNC)是独立预后因素,阳性PLNC与更差的生存相关。

研究设计与样本

  • 共纳入282例患者(NCT+CCRT组136例,CCRT组146例),采用倾向性评分匹配(PSM)按1:1比例匹配后得到85对患者。
  • 比较匹配后两组生存 outcomes,并用Cox回归模型识别预后因素。

主要发现

  • 匹配后NCT+CCRT组与CCRT组的5年OS分别为81.0% vs. 77.5%(P=0.750),LRFS为85.8% vs. 88.1%(P=0.495),DRFS为92.5% vs. 93.9%(P=0.759),RFS为81.0% vs. 77.5%(P=0.919)。
  • 多因素分析显示吸烟史(P=0.044)和T分期(P=0.027)是OS的独立预后因素,淋巴结直径(P=0.032)是LRFS的独立预后因素。
  • PLNC是DRFS(P=0.007)和RFS(P=0.009)的独立预后因素;PLNC阳性组较阴性组5年OS更低(82.7% vs. 94.1%,P=0.014),DRFS更低(79.3% vs. 96.2%,P=0.003),RFS更低(62.4% vs. 86.8%,P=0.001)。
  • NCT+CCRT组急性血液学3-4级不良事件发生率高于CCRT组(P<0.05),非血液学3-4级不良事件率两组无显著差异(P>0.05)。

关键数值与推荐

  • PLNC定义为淋巴结坏死或融合。
  • PLNC阳性较阴性者5年OS 82.7% vs. 94.1%(P=0.014),DRFS 79.3% vs. 96.2%(P=0.003),RFS 62.4% vs. 86.8%(P=0.001)。

临床怎么用

  • 对于T3-4N1期鼻咽癌,不应常规推荐新辅助化疗以改善生存,需权衡血液学毒性风险。
  • 治疗前应评估淋巴结坏死或融合(PLNC状态),阳性者预后较差,可能需要更密切随访或强化治疗策略。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • 样本量有限,倾向性匹配后仅85对患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To estimate the efficacy of neoadjuvant chemotherapy (NCT) in stage T3-4N1 nasopharyngeal carcinoma (NPC). METHODS: Data on stage T3-4N1 NPC patients treated with concurrent chemoradiotherapy (CCRT) with or without NCT at the Sun Yat-sen University Cancer Center between January 2006 and December 2013 were retrospectively reviewed. Propensity score matching (PSM) was carried out to balance prognostic factors in NCT followed by CCRT (NCT + CCRT) group and CCRT group in a 1:1 ratio. Survival outcomes of matched patients in the two groups were compared, and prognostic factors were identified using Cox regression model. RESULTS: A total of 282 patients were involved in this study, with 136 of NCT + CCRT group and 146 of CCRT group. After PSM, 85 pairs of patients were selected. There were no significant differences in 5-year overall survival (OS), locoregional recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and recurrence-free survival (RFS) between NCT + CCRT group and CCRT group (81.0% vs. 77.5%, P = 0.750; 85.8% vs. 88.1%, P = 0.495; 92.5% vs. 93.9%, P = 0.759; 81.0% vs.77.5%, P = 0.919, respectively). Multivariate analysis found that smoking history (P = 0.044) and T classification (P = 0.027) were independent prognostic factors for OS, lymph node diameter (P = 0.032) was independent prognostic factor for LRFS, positive pretreatment lymph node condition (PLNC), which was defined as the lymph node necrosis or confluent, was independent prognostic factor for DRFS (P = 0.007), and RFS (P = 0.009). Lower 5-year OS (82.7% vs. 94.1%, P = 0.014), DRFS (79.3% vs. 96.2%, P = 0.003), and RFS (62.4% vs. 86.8%, P = 0.001) were found in positive PLNC group compared with negative PLNC group. In terms of toxicities, the incidences of acute hematological Grade 3-4 adverse events (AEs) were higher in NCT + CCRT group compared with CCRT group (P < 0.05), while no significant difference was observed in the rates of non-hematological Grade 3-4 AEs between these two groups (P > 0.05). CONCLUSIONS: Additional NCT is not associated with improved survival outcomes for patients with stage T3-4N1 NPC, but bring increased hematological Grade 3-4 AEs. PLNC is independent prognostic factor in stage T3-4N1 NPC, with positive PLNC correlating with poor survival outcomes.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang L, Wu Z, Xie D, et al. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis. Radiat Oncol. 2020. PMID: 32615984. doi:10.1186/s13014-020-01594-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。